Related Experiment Video
Updated: May 5, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
FDA 2025 Cancer Drug Approvals: targeted therapy dominates
1Medical Sciences, Dx-Rx Institute, 3480 Fredensborg, Denmark.
Abstract:
This commentary discusses the FDA's drug approvals in 2025, with a particular focus on cancer therapies and the role of companion diagnostics (CDx). Cancer has emerged as the leading therapeutic area, accounting for 35% of all new drug approvals, largely driven by targeted therapies, with kinase inhibitors representing nearly half of these drugs. Many of the drugs have received orphan drug designations and/or have utilized the Accelerated Approval Program. A key finding was the widespread adoption of the drug-diagnostic co-development model, in which a CDx assay is developed along with the drug and used for patient selection in clinical trials. However, a significant challenge is the frequent lack of concurrent drug and CDx assay approvals. The absence of an analytically and clinically validated CDx assay may pose a challenge for healthcare providers in accurately identifying eligible patients, potentially delaying access to appropriate therapy. The FDA's cancer drug approvals for 2025 highlight an ongoing commitment to precision medicine, with several new targeted treatments, such as antibody-drug conjugates and kinase inhibitors, where CDx assays play an important role in identifying the appropriate patient population.
Insights
The FDA
Area of Science:
- Oncology
- Pharmacology
- Medical Diagnostics
Background:
- Cancer is the leading therapeutic area for FDA drug approvals, comprising 35% of new drugs in 2025.
- Targeted therapies, particularly kinase inhibitors, dominate new cancer drug approvals.
- Many cancer drugs utilize orphan drug designations and the FDA's Accelerated Approval Program.
Purpose of the Study:
- To analyze the FDA's 2025 drug approvals, focusing on cancer therapies and companion diagnostics (CDx).
- To examine the increasing adoption of the drug-diagnostic co-development model for precision medicine.
- To identify challenges in the concurrent approval of drugs and their associated CDx assays.
Main Methods:
- Review of FDA drug approval data for 2025.
- Analysis of therapeutic areas, drug classes, and regulatory pathways.
- Assessment of the drug-diagnostic co-development model and its challenges.
Main Results:
- Cancer therapies represented 35% of 2025 FDA drug approvals, driven by targeted agents like kinase inhibitors.
- Widespread adoption of the drug-diagnostic co-development model was observed.
- A significant challenge identified is the frequent lack of simultaneous approval for drugs and their companion diagnostic assays.
Conclusions:
- FDA's 2025 approvals underscore a commitment to precision medicine in oncology.
- The co-development of drugs and companion diagnostics (CDx) is crucial for targeted therapies.
- Lack of concurrent CDx assay approval hinders timely patient access to innovative cancer treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
02:56Treatment Resistent Cancers
02:49Cancer Therapies